Literature DB >> 14584878

Antigen-specific B-lymphocyte activation.

Gail A Bishop1, Sokol A Haxhinasto, Laura L Stunz, Bruce S Hostager.   

Abstract

B lymphocytes comprise a major component of the adaptive mammalian immune system, having the exclusive ability to produce and secrete immunoglobulins (Ig) of various forms (isotypes). This property alone renders B-cell activation critical to immunity, but the fully activated B cell also functions in antigen presentation and the production of a variety of cytokines and chemokines. There are many signals that must be coordinated to achieve and properly regulate antigen-specific B-lymphocyte activation and the development of humoral memory. This review seeks to summarize these components, and to highlight recent advances in each area that contribute to a greater understanding of the complex processes involved in B-cell activation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14584878     DOI: 10.1615/critrevimmunol.v23.i3.10

Source DB:  PubMed          Journal:  Crit Rev Immunol        ISSN: 1040-8401            Impact factor:   2.214


  16 in total

Review 1.  Toll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responses.

Authors:  Egest J Pone; Hong Zan; Jingsong Zhang; Ahmed Al-Qahtani; Zhenming Xu; Paolo Casali
Journal:  Crit Rev Immunol       Date:  2010       Impact factor: 2.214

2.  Syk mediates BCR- and CD40-signaling integration during B cell activation.

Authors:  Haiyan Ying; Zhenping Li; Lifen Yang; Jian Zhang
Journal:  Immunobiology       Date:  2010-10-07       Impact factor: 3.144

3.  Polymer blend particles with defined compositions for targeting antigen to both class I and II antigen presentation pathways.

Authors:  Kenny K Tran; Xi Zhan; Hong Shen
Journal:  Adv Healthc Mater       Date:  2013-10-02       Impact factor: 9.933

4.  Enhanced Toll-like receptor (TLR) responses of TNFR-associated factor 3 (TRAF3)-deficient B lymphocytes.

Authors:  Ping Xie; Jayakumar Poovassery; Laura L Stunz; Sonja M Smith; Mark L Schultz; Lindsey E Carlin; Gail A Bishop
Journal:  J Leukoc Biol       Date:  2011-10-04       Impact factor: 4.962

5.  Differential role of reactive oxygen species in the activation of mitogen-activated protein kinases and Akt by key receptors on B-lymphocytes: CD40, the B cell antigen receptor, and CXCR4.

Authors:  Rosaline L Lee; Jens Westendorf; Michael R Gold
Journal:  J Cell Commun Signal       Date:  2007-05-10       Impact factor: 5.782

6.  Antigen receptor signals rescue B cells from TLR tolerance.

Authors:  Jayakumar S Poovassery; Tony J Vanden Bush; Gail A Bishop
Journal:  J Immunol       Date:  2009-07-31       Impact factor: 5.422

7.  A polypyrimidine tract-binding protein-dependent pathway of mRNA stability initiates with CpG activation of primary B cells.

Authors:  Joseph F Porter; Stefano Vavassori; Lori R Covey
Journal:  J Immunol       Date:  2008-09-01       Impact factor: 5.422

8.  Characterization of Thymus-dependent and Thymus-independent Immunoglobulin Isotype Responses in Mice Using Enzyme-linked Immunosorbent Assay.

Authors:  Almin I Lalani; Sining Zhu; Ping Xie
Journal:  J Vis Exp       Date:  2018-09-07       Impact factor: 1.355

Review 9.  TRAF3 as a powerful and multitalented regulator of lymphocyte functions.

Authors:  Gail A Bishop
Journal:  J Leukoc Biol       Date:  2016-05-06       Impact factor: 4.962

10.  Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection.

Authors:  Marc C Levesque; M Anthony Moody; Kwan-Ki Hwang; Dawn J Marshall; John F Whitesides; Joshua D Amos; Thaddeus C Gurley; Sallie Allgood; Benjamin B Haynes; Nathan A Vandergrift; Steven Plonk; Daniel C Parker; Myron S Cohen; Georgia D Tomaras; Paul A Goepfert; George M Shaw; Jörn E Schmitz; Joseph J Eron; Nicholas J Shaheen; Charles B Hicks; Hua-Xin Liao; Martin Markowitz; Garnett Kelsoe; David M Margolis; Barton F Haynes
Journal:  PLoS Med       Date:  2009-07-07       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.